Opus Genetics Files Definitive Proxy Statement and Sends Letter to Stockholders Highlighting the Company's Transformation and Progress

Board Comments on Misguided Campaign from Mina Sooch to Replace a Majority of Opus' Directors and Promote a Flawed Strategy Urges Stockholders to Vote on the BLUE Proxy Card FOR All Nine of the Company's Nominees RESEARCH TRIANGLE PARK, N.C., April 07, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. ("Opus" or the "Company") (NASDAQ:IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and therapies for other ophthalmic disorder ...